

STABLON[®]

Tianeptine sodium

COMPOSITION

One coated tablet dosed at 12.5 mg of Tianeptine sodium.

Excipients with known effect: sucrose.

DESCRIPTION

Oval shape tablet, white in color.

THERAPEUTIC INDICATION

This drug is recommended in the treatment of major depressive episodes mild, moderate, or severe.

POSODOLOGY AND METHOD OF ADMINISTRATION

The recommended dosage is one tablet containing 12.5 mg three times a day (morning, midday and evening) at the beginning of the main meals.

Special populations

Elderly subjects

The efficacy and safety of tianeptine have been established in elderly depressed patients (≥ 65 years) (see section Pharmacodynamic Properties). No dose adjustment is required in relation to age.

In frail elderly patients (< 55 kg) and elderly patients with moderate renal failure, the dosage should be restricted to 2 tablets per day (see section Pharmacokinetic Properties).

Renal Failure

In patients with severe renal failure ($\text{ClCr} < 19$ ml/min), the posology should be restricted to 2 tablets per day (see section Pharmacokinetic Properties).

Hepatic impairment

In patients with severe cirrhosis (Class C, Child Pugh Score), the posology should be restricted to 2 tablets per day (see section Pharmacokinetic Properties).

In chronic alcoholic patients, irrespective of whether they have mild or moderate cirrhosis or no cirrhosis, the posology does not need to be adjusted (see section Pharmacokinetic Properties).

Paediatric population

The safety and efficacy of tianeptine in children and adolescents under 18 years of age have not been determined. There is no data available. Stablion should not be used in adolescents aged 15 to 18 years old (see section Special warnings and precautions for use).

Tianeptine is contraindicated in children and adolescents under 15 years old (see section Contraindications).

Discontinuation of treatment

Abrupt discontinuation of the treatment should be avoided. The dosage should be gradually reduced over a period of 7 to 14 days in order to reduce the risk of withdrawal reactions (see sections Special warnings and precautions for use).

Method of administration

Oral route

CONTRAINDICATIONS

- Hypersensitivity to tianeptine or to any of the excipients
- Pregnancy or breastfeeding
- Children and adolescents under 15 years old.

SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Suicide/suicidal thoughts or clinical worsening

Depression is associated with an increased risk of suicidal thoughts, self-harming and suicide (suicidal behaviour). This risk persists until a significant remission has been obtained. Clinical improvement may not be obtained until after several weeks of treatment, therefore, patients must be closely monitored until this improvement has been achieved. Clinical experience shows that the risk of suicide can increase during the very early stages of recovery.

Patients with a history of suicidal type behaviour or those expressing significant suicidal thoughts before starting the treatment face a higher risk of the onset of suicidal thoughts or suicidal type behaviour, and must be closely monitored during treatment. A meta-analysis of placebo-controlled clinical trials of the use of antidepressants in adults displaying psychiatric disorders has revealed an increase in the risk of suicidal behaviour in patients under 25 years of age who were being treated with antidepressants compared to those receiving a placebo. Careful monitoring of patients, and particularly of high-risk patients, must accompany the use of this drug treatment, particularly at the beginning of treatment and at times of dose changes.

The patients (and their family and friends) must be warned of the need to monitor for the onset of clinical worsening, the appearance of suicidal thoughts/behaviour and any abnormal change of behaviour, and to seek medical advice immediately if such symptoms arise.

In case of general anaesthesia is necessary, the anaesthetist should be informed of the treatment, and the treatment discontinued 24 or 48 hours prior to surgery.

In case of emergency, surgery may still be performed without prior discontinuation; under peroperative monitoring should be performed.

As with all psychotropic treatments, the administration of this medicinal products with alcoholic beverages or medicinal products containing alcohol is advisable.

Do not exceed the recommended doses.

Abuse/dependence and withdrawal syndrome

In case of a history of drug dependence or alcohol dependence, the patients must be very closely monitored in order to avoid any increase in dosage.

After discontinuation of treatment with tianeptine, withdrawal symptoms have been observed in some patients. The following events have been observed: anxiety, muscle pain, abdominal pain, insomnia, joint pain. When the treatment is started, the patient should be informed on the risk of withdrawal syndrome at discontinuation.

If the treatment is to be interrupted, the dosage should be gradually reduced over a period of 7 to 14 days in order to reduce the risk of withdrawal reactions (see section Posology and Method of Administration).

A combination with MAOI is inadvisable (see section **Interaction with other medicinal products and other forms of interaction**). It is necessary to allow a free interval:

- of two weeks when tianeptine is used as a replacement of MAOI,
- of 24 hours when a MAOI is used as a replacement of tianeptine.

Hyponatraemia

Hyponatraemia, probably due to a syndrome of inappropriate anti-diuretic hormone secretion (SIADH), has been reported with the use of tianeptine. The majority of cases were reported in the elderly, especially when coupled with a recent history of, or condition pre-disposing to, altered fluid balance. Caution should be exercised in patients at increased risk for hyponatraemia, such as elderly, cirrhotic, or dehydrated patients or those treated with diuretics.

This medicinal product contains sucrose. Its use is inadvisable in patients with fructose intolerance, glucose and galactose malabsorption syndrome or sucrase-isomaltase deficiency (rare hereditary diseases).

Level of sodium

This medicine contains less than 1 mmol sodium (23 mg) per coated-tablet, i.e. is essentially 'sodium free'.

Paediatric population:

Stablon is contraindicated in children and adolescents under 15 years old (see section Contraindications) and should not be used in adolescents aged 15 to 18 years old. Suicidal type behaviours (suicide attempts and suicidal thoughts) and hostile type behaviour (mainly aggressiveness, opposition behaviour and anger) behaviour has been observed more frequently during clinical studies in children and adolescents treated with antidepressants compared to those treated with placebo. If the decision to treat is nonetheless taken, in case of clinical need, the patient must be closely monitored to detect the appearance of suicidal symptoms. Furthermore,

there is no long term safety data in children and adolescents, concerning growth, sexual maturation and cognitive and behavioural development.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION

Combinations that are inadvisable

- **irreversible MAOIs (iproniazide)** : due to risk of cardiovascular collapse or paroxysmal hypertension, hyperthermia, convulsions, death.

FERTILITY, PREGNANCY AND LACTATION

Pregnancy

In a peri- and postnatal study, increased post-implantation and post natal losses were observed in rats at a maternotoxic dose (Preclinical safety data).

There are no or limited data (less than 300 pregnancy outcomes) from the use of tianeptine in pregnant women. Therefore, it is preferable not to use tianeptine during pregnancy whatever the term.

It is preferable to maintain a balanced maternal psychic equilibrium throughout pregnancy. If tianeptine is necessary to ensure this balance, treatment should be initiated or continued at the necessary dose throughout pregnancy and if possible as monotherapy and the pharmacological profile of the molecule should be taken into account when monitoring the newborn baby.

Lactation

Dysgalactia in the dams was observed in rats at a maternotoxic dose (see section Preclinical safety data).

Tricyclic antidepressants are excreted into breast milk, and thus breast feeding is not recommended during treatment.

Fertility

In rats, a fertility study showed decreased reproductive performances (increase in preimplantation losses) at a maternotoxic dose (see section Preclinical safety data).

In humans, no clinical data are available.

EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

Diminished alertness could appear in some patients. Therefore, the attention of drivers and users of machines should be drawn to the risks of drowsiness attached to the use of this medicinal product.

UNDESIRABLE EFFECTS

Summary of the safety profile:

The undesirable effects observed with tianeptine during clinical trials are moderate in intensity. They consist primarily of nausea, constipation, abdominal pain, drowsiness, headaches, dry mouth and vertigo.

Table of undesirable effects

The following undesirable effects have been observed during clinical trials and/or post-MA use of tianeptine and are classified as a function of their frequency:

Very common ($\geq 1/10$); common ($\geq 1/100$, $< 1/10$); uncommon ($\geq 1/1,000$, $< 1/100$); rare ($\geq 1/10,000$, $< 1/1,000$); very rare ($< 1/10,000$), and not known (cannot be estimated from the

available data).

System Organ-Class (SOC)	Frequency	Undesirable effects
Metabolism and nutrition disorders	Common	Anorexia
	Not known*	Hyponatraemia
Psychiatric disorders	Common	Nightmares
	Uncommon	Abuse, dependence, in particular in subjects under 50 years of age with a history of drug-dependence or alcohol-dependence
	Not known*	Cases of suicidal thoughts and behaviour have been reported during treatment with tianeptine or shortly after its discontinuation (see section Special warnings and precautions for use) Confusional state, hallucinations
Nervous system disorders	Common	Insomnia
		Somnolence
		Dizziness
		Headaches
		Pre-syncope
	Tremors	
Not known*	Extrapyramidal disorders Dyskinaesia	
Cardiac disorders	Common	Tachycardia
		Extrasystoles
		Chest pain
Vascular disorders	Common	Hot flushes
Respiratory, thoracic and mediastinal disorders	Common	Dyspnoea
Gastrointestinal disorders	Common	Gastralgia
		Abdominal pain
		Dry mouth
		Nausea
		Vomiting
		Constipation Flatulence
Skin and subcutaneous tissue disorders	Uncommon	Maculopapular or erythematous rash
		Pruritus

System Organ-Class (SOC)	Frequency	Undesirable effects
	Not known*	Urticaria
		Acne
		Exceptional bullous reactions
Musculoskeletal and systemic disorders	Common	Myalgia Lumbar pain
		Common
Hepato-biliary disorders	Not known*	

*Post-marketing data**

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via e-meso subsite at <https://e-meso-pom.go.id>, or reporting to Pusat Farmakovigilans/MESO Nasional, Badan Pengawas Obat dan Makanan: Phone: (+62 21) 4244691 Ext. 1079 and Email: pv-center@pom.go.id.

OVERDOSE

Symptoms

The experience concerning acute tianeptine intoxication cases (maximum quantity: 2250 mg, ingested in a single dose) primarily revealed alertness disorders which can lead to coma, especially in case of multiple intoxications.

Recommended procedure

Tianeptine has no known specific antidote. In case of acute intoxication, a symptomatic treatment and routine monitoring must be started. Medical monitoring in a specialised setting is recommended.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties

Pharmacotherapeutic group: OTHER

ANTIDEPRESSANTS

ATC code: N06AX14

Mechanism of action

Tianeptine is an antidepressant.

In animals, tianeptine has the following properties:

- Tianeptine increases the spontaneous activity of pyramidal cells in the hippocampus and accelerates their recovery after functional inhibition,
- Tianeptine increases the rate of serotonin re-uptake by

neurons in the cortex and hippocampus.

In vitro, tianeptine has no affinity for monoaminergic receptors and does not inhibit serotonin (5-HT), noradrenaline (NA) or dopamine (DA) re-uptake. Tianeptine can modulate synaptic glutamatergic neuro-transmission.

The specific contribution of each effect to the antidepressant activity is unknown.

Clinical efficacy and safety

Four double-blind placebo-controlled trials have been performed to investigate the short-term efficacy of tianeptine in major depressive disorder in adults, one with fixed doses (37.5 mg, 75 mg) and two with possible dose up-or-down titration (initial dose 37.5 mg, then 25, 37.5 or 50 mg) and one in elderly patients (311 patients aged 65 years and above; ~100 patients by treatment arm, including ~20 patients above 75 years in each arm) with a potential dose increase according to patient improvement after 2 weeks of treatment (25 mg then 25 mg or 50 mg). In the adult studies, primary endpoint was change in MADRS total score from baseline for the fixed and flexible dose trials.

At the end of treatment (6 weeks), the efficacy of tianeptine was significant in the two flexible dose trials but not in the fixed dose trial. In a trial, imipramine, used as an active comparator, demonstrated the sensitivity of the trial.

The maintenance of the antidepressant efficacy was evaluated in a relapse and recurrence prevention trial. Patients considered as responding to treatment by the investigator (6 weeks of "open" treatment with tianeptine at a daily dosage of 2 to 4 tablets, i.e. 25 to 50 mg daily) were randomised to tianeptine or placebo for an additional duration of 16.5 months. Tianeptine showed a statistically significant efficacy superiority with respect to placebo ($p < 0.001$) on the main criterion of the trial: prevention of relapse or recurrence measured by the time to their onset. The incidence of relapse after 6 months of double-blind follow-up was 6% for tianeptine and 22% for placebo. The incidence of relapse or recurrence after 18 months of double-blind follow-up was 16% for tianeptine and 36% for placebo.

Pharmacokinetic properties

Absorption

Gastrointestinal absorption is rapid and complete.

Distribution

Distribution is rapid, and is associated with a high level of protein binding of nearly 94%, primarily to albumin.

Biotransformation

Tianeptine is extensively metabolised by the liver, primarily by beta-oxidation, without CYP450 involvement. Its main metabolite, pentanoic acid (MC5), is active and less potent than tianeptine.

Elimination

The elimination of tianeptine is characterised by a short terminal half-life of 3 h, most of the metabolites are excreted in the urine.

Elderly, very elderly and fragile patients

In elderly subjects, tianeptine plasma concentrations increased by 30% and those of MC5 were nearly doubled after single or repeated administration, compared to that of younger patients (see section **Posology and method of administration**).

In very elderly (87 ± 5 years) or fragile (45 ± 9 kg), a significant increase of C_{max} and exposure (area under the curve, AUC) to tianeptine and MC5 were observed after a single administration (see section **Posology and method of administration**).

Patients with severe renal failure ($Cl_{Cr} < 19$ ml/min)

The pharmacokinetics of tianeptine remain unchanged but the exposure to MC5 is nearly doubled after single and repeated administration (see section **Posology and method of administration**).

Patients with severe liver cirrhosis (Class C, Child-Pugh Score)

Exposure to tianeptine and MC5, after the administration of a 12.5 mg dose, are increased compared to that of adult depressive patients (see section **Posology and method of administration**).

In case of milder cirrhosis, such as chronic alcoholics, the effects on the pharmacokinetic parameters are insignificant (see section **Posology and method of administration**).

Preclinical safety data

Non-clinical data from conventional genotoxicity and carcinogenesis studies have not revealed any specific risk for humans.

In the fertility study, an increase in pre-implantation losses was observed at the maternotoxic dose of 45 mg/kg/day (i.e. 12 times the human dose determined with respect to the body surface).

Tianeptine is not teratogenic in rats and rabbits.

In the peri- and post-natal study, a lactic secretion dysfunction and an increase in post-implantation and post-natal losses have been observed in rats at the maternotoxic dose of 45 mg/kg/day (i.e. 12 times the human dose determined with respect to the body surface).

STORAGE CONDITIONS

Store below 30°C.

Shelf life : 3 years.

Reg. No. : DKL1704524816A1

ON MEDICAL PRESCRIPTION ONLY

HARUS DENGAN RESEP DOKTER

Manufactured by :

PT. Darya-Varia Laboratoria
Tbk

Underlicense of :

